Funding for this research was provided by:
Cancer Research UK (C1287/A16563, C1287/23382, C12292/A20861, C1287/A17523, C12292/A11174)
National Cancer Institute (UM1 CA164920)
Deutsche Krebshilfe (grant no 110837)
KWF Kankerbestrijding (NKI2007-3756, NKI2004-3088, NKI1998-1854)
European program ERA-NET on Translational Cancer Research (TRANSCAN-JTC2012, n°2014-008)
Genome Canada and the Canadian Institutes of Health Research (GPH-129344)
Text and Data Mining valid from 2020-01-16
Received: 7 June 2019
Accepted: 5 January 2020
First Online: 16 January 2020
Ethics approval and consent to participate
: Participants provided written informed consent, and studies were approved by a relevant ethics committee.
: Not applicable
: Wendy Chung reports potential conflict of interest from Regeneron and Biogen; Olivier Caron from AstraZeneca and IPSEN; Pascal Pujol, AstraZeneca, Genomic Health and Roche; D Gareth Evans, AstraZeneca and AmGen; Ros Eeles, Janssen-Cilag; Diane Eccles, Pierre Fabre, AstraZeneca; Karin Kast, Roche Pharma AG; and David Goldgar, University of Utah Foundation and Ambry Genetics. Anne-Marie Gerdes participated in an Advisory Board Meeting London in 2016, sponsored by Astra Zeneca about BRCA-testing in ovarian cancer.